Deep vein thrombosis (DVT) is where a blood clot forms in a vein that is deep in your body, and sometimes, its symptoms can be felt in behind your knee when the clot is formed or forming in the popliteal vein. This can be fatal if the clot breaks off and travels to the heart or lungs, which can cause pulmonary embolism.
This is what had happened to NBC war journalist David Bloom, 39, who died from DVT in April 2003 when he was covering the Iraq War in Iraq. His wife, Melanie, raised a national awareness to DVT since then, including features on Larry King Live and Oprah. Personally, my own writing composition teacher, Mr. Gary Bradshaw, who taught at Rancho Bernardo High School, died from a similar condition during the Christmas season of 1994.
Also known as postphlebitic syndrome, post-thrombotic syndrome, and thromboembolism, deep vein thrombosis can be a quick and silent killer like a heart attack if the symptoms are ignored or not as obviously noticed. This article focuses mostly on DVT of the leg.
Thrombosis vs embolus
Simply put, a thrombosis is a blood clot that is formed in a vein or artery. Embolus refers to the actual piece of blood clot or a similar object, and embolism is where that piece gets stuck in a blood vessel which blocks blood flow. Therefore, not all thrombosis becomes embolism (but it is a significant risk factor) and not all embolism is thrombosis. For this article, DVT focuses primarily to a blood clot behind the knee in the popliteal vein and femoral vein.
Deep vein thrombosis symptoms
The deep vein thrombosis in the back of the knee is the most common type of venous thrombosis and causes inflammation of the blood vessel, swelling of the knee, ankle, and/or foot. However, about half of the people who have DVT do not have any symptoms, according to the Center for Disease Control (CDC). Oftentimes, warning signs of deep vein thrombosis occur below the knee, and these include pain behind the knee, muscle cramp in the calf of the affected leg, tenderness in the back of the knee or lower leg, affected skin area looks reddish or bluish, and the skin feels a lot warmer than nearby skin.
For those who have asymptomatic DVT, they may know they have it until the blood clot reaches one of the lungs, which is called pulmonary embolism. This can be fatal and they would need emergency care.
Other symptoms may be similar to a heart attack, like chest pain or discomfort that worsens with coughing or deep breathing, troubled breathing, irregular heartbeat, and very low blood pressure—particularly in a systolic reading where it measures blood pressure in the veins that pumps blood back to the heart.
Deep vein thrombosis causes
Various risk factors contribute to developing a blood clot in the leg. These include reduced blood flow due to lack of movement (e.g. bed rest, sedentary lifestyle, injury to the vein from physical trauma, surgery, venous previous DVT, drug abuse via injections), increase venous pressure (due to various factors such as pregnancy and stenosis), increased blood thickness, genetics, diabetes, smoking, chemotherapy for cancer, and sepsis.
Even anatomical variations of the lower limb’s venous system can affect the likelihood of getting deep vein thrombosis. Several researchers in Qatar gathered data from 637 patients with DVT at Hamad General Hospital in Doha from 2008 to 2012, and they found that pulmonary embolism from DVT is more common in the left lower leg than the right one. Those with DVT on both legs are more likely to get it again, as well as pulmonary embolism and higher mortality. Also, patients with DVT closer to the hip have a higher mortality rate than those with DVT toward the lower leg.
They found that obesity is another risk factor of getting DVT because of increased compression of the veins in the upper and lower legs. Two common areas where DVT occur where the vein bends with the joint, such as the knee and groin. These areas include the popliteal vein (74%), profunda femoral vein (74%), and common femoral vein (50.4%). Some patients in the sample have more than one site of blood clots.
Mortality from DVT is quite high. An 2019 narrative review of DVT published in The Medical Journal of Australia states that about 6% of patients with DVT will likely die within 30 days, mostly from pulmonary embolism. That percentage increases to 13% if the patients are diagnosed with pulmonary embolism.
Even if treatment is successful, about 20% to 50% of these patients would develop post-thrombotic syndrome, a condition where there is damage to the valves in the veins due to DVT. About 3% of these patients get chronic thromboembolic pulmonary hypertension (high blood pressure in the lung’s arteries), and there is a 40% recurrence of lower body DVT within 10 years after three to six months of anticoagulation treatment.
Another study of more than 5,000 patients in Beijing, China, found that patients with respiratory diseases, elderly patients in long-term care in general, and those with “internal medicine” diseases are more likely to develop DVT than those with physical trauma, surgery for bone fractures, or other types of invasive procedures.
Deep vein thrombosis treatments
Basically, treatments for deep vein thrombosis is to minimize the risk of getting post-thrombotic syndrome, another blood clot, and pulmonary embolism. Because every patient with DVT has a unique health history, beliefs about treatments and their own health, and other biopsychosocial factors, there are no cookie-cutter approaches to DVT treatments. Always consult your physician for your personal treatment. This article is not a substitution for your personal medical advice and care.
Because viscous blood increases the likelihood of developing a blood clot, anticoagulants may be used to treat DVT and its related conditions. The National Institute for Health and Care Excellence (NICE) suggests that anticoagulants should be used for those with proximal DVT (toward the hip) rather than distal DVT (toward and below the knee).
The guidelines also consider the risks vs. benefits of taking anticoagulants because the treatment may likely cause more harm to certain populations or individuals than good. For example, the American College of Chest Physicians recommends that patients with a symptomatic blood clot in the hepatic vein should get anticoagulant therapy, while those who had such “incidentally detected” cases should not get such therapy. Still, the college suggests that clinicians should consider individual differences (e.g. diabetes, obesity, lifestyle) and preference of treatments.
Although anticoagulants are the standard of treatment for most patients with DVT—particularly for venous thromboembolism (VTE)—there is some evidence that suggests treatment duration and the type of deep vein thrombosis can affect the outcome. A 2020 Cochrane Review of eight randomized controlled trials with a total of more than 1,200 subjects found that anticoagulant therapy with vitamin K had “little to no difference in major bleeding events.” However, the amount of bleeding reviewed was clinically significant compared to the control groups that had no intervention or a placebo. In other words, the data results show a tiny effect that appears to have little to no impact, but among those patients with bleeding, it may likely warrant clinicians to use extra caution when recommending anticoagulants.
Five of the trials in the Cochrane Review compared patients with anticoagulation treatments for up to three months and those without anticoagulation, while the other three trials compared anticoagulation treatments with different time frames. While the treatment shows a significantly greater reduction of risk of getting VTE again, there is “no clear effect on the risk” of getting a pulmonary embolism recurrence.
Three months of anticoagulant treatments was shown to be better than shorter treatments that last up to six weeks in reducing the risk of getting VTE again. However, all trials show “no clear difference” in all types of bleedings.
Thrombolysis is the removal of a blood clot from a blood vessel by using medications that dissolve the clot. A catheter is inserted into the vein in a process called percutaneous coronary intervention to deliver the meds.
The NICE guidelines suggest that such therapy should be used for those with symptomatic DVT in the iliofemoral vein that lasts less than 14 days, have a life expectancy of one year or more, fairly functioning in daily activities, and have a low risk of bleeding.
However, there is not much high-quality evidence that shows thrombolysis for lower limb DVT is safer in terms of risk of bleeding versus other types of treatment. The most recent systematic review of 45 qualified studies with 4,740 subjects found that thrombolysis increases the risk of major bleeding, including bleeding within the skull, even though the intervention can “probably reduce mortality” among patients with pulmonary embolism and post-thrombotic syndrome. The level of certainty ranks “moderate” and “low,” respectively, which measures how reliably the data are.
“Stakeholders involved in the decision making process would need to weigh these effects to define which clinical scenarios merit use of thrombolytic therapy for patients presenting with acute VTE,” the researchers concluded.
Inferior vena cava filter
The inferior vena cava filter (IVC) is an implant used to prevent blood clots from entering the lungs for patients who are at risk of repeated clots. This device is usually recommended if anticoagulants are contraindicated.
A 2011 systematic review of 37 non-randomized trials of more than 6,800 patients found that it seems to be effective for preventing pulmonary embolism, but there is a lack of consistency of such prevention in two of the studies, the authors wrote.
There is also a risk of increased incidences of DVT closer to the groin. For example, one study found that there is nearly a 21% chance of getting DVT after two years of using an IVC filter versus nearly 12% in the anticoagulation group. Eight years of usage of the IVC filter furthered increased the chance of getting DVT to 37% while the anticoagulant group had 27.5%.
In 2018, another systematic review of seven qualified trials found that there was “no significant difference” in mortality rate, DVT, and pulmonary embolism recurrence, or bleeding. Because of the inconsistent experimental setup, small sample sizes, and lack of randomized controlled trials, the researchers concluded that “insufficient data exist on the efficacy of retrievable IVC filters,” as well as safety concerns. However, they said that this does not mean IVC filters do not work to prevent pulmonary embolism. Like anticoagulants and thrombolytic treatments, it is mostly a matter of risks versus benefits.
Compression stockings and similar compressive legwear for the lower leg is often used to reduce or prevent future occurrences of deep vein thrombosis. Although the mechanism of how it works is uncertain, a 2016 systematic review from Switzerland found there is evidence that show both benefits and no benefits of using compression stockings for DVT. Out of five randomized controlled trials with a total of nearly 1,400 patients, only one trial showed no benefit. Because of the limited number of studies included and the mixed methods of the experiments, the researchers “refrained from pooling the results” of the trials.
A 2018 Cochrane Review has a comprehensive investigation that covered 20 randomized controlled trials with 1,681 patients total. The researchers explored and evaluated the effectiveness and safety of compression stockings among DVT patients who were hospitalized and had different interventions, such as cardiac surgery or neurosurgery.
While the overall data finds that the stockings had decreased the number of DVT incidents, small sample sizes limit the statistical power of the meta-analyses, meaning that the results may have a good chance of being a type I error (false positive). Most of the trials used only stockings that reach mid-thigh, so there is not enough evidence to conclude what other lengths of stockings can do. Even so, the researchers broke down three levels of evidence of what compression stockings could do:
- High-quality evidence suggests that compression stockings can prevent DVT in a clinical setting, particularly among surgical patients.
- Moderate-quality evidence suggests that compression stockings may prevent DVT at the proximal level (toward the groin).
- Low-quality evidence finds that compression stockings can prevent pulmonary embolism. Only two of the five trials reported about pulmonary embolism and the results were “inconsistent.”
Exercise may likely reduce your risk of getting deep vein thrombosis, particularly venous thromboembolism. A meta-analysis of 12 papers with a total of 14 different observational prospective cohort studies had a total of more than 1.28 million subjects and more than 23,700 VTE cases. This type of cohort study follows a group of people over a period of time and examines a condition that cannot be done experimentally (often due to ethical reasons).
Basically, regular exercise—especially those that involve the lower body such as walking and cycling—can increase blood flow in the veins, reducing the risk of getting a blood clot. So, try to get as much movement as you can each day and everyday. The Physical Activity Guidelines Advisory Committee Scientific Report recommends that adults should get between 2.5 to five hours of moderate-intensity physical activity per week or 1.5 hours to 2.5 hours of vigorous exercise per week. This can be combination of walking, hiking, gym workouts, swimming, social dancing, and gardening.
However, considering that many adults are unable to get anywhere near that amount, some of them may need to take baby steps to gradually reach the minimum amount.
Massage therapy and deep vein thrombosis
Massage therapists who work with patients or clients with deep vein thrombosis should take extra caution when doing their health history intake and applying hands-on work. A recent case report from Chang Mai University in Thailand documented a 25-year-old pregnant woman who had dyspnea (difficulty in breathing) and lapse in and out of consciousness after receiving a five- to ten-minute foot and lower leg massage that often is used initially during a traditional Thai massage.
She later had seizures, became unconscious and had cardiac arrest. After her life was saved by first responders and was sent to a local hospital, clinicians found that she had pulmonary embolism that stems from a blood clot that was in the lower leg, which was undetected until the fatal symptoms occurred.
The authors suggested that pregnant women should “avoid leg massage unless they are certain that no thromboembolism disorders exist.” Massage therapists must do a thorough health intake, particularly about deep vein thrombosis, cardiac health history, and lifestyle that may affect the likelihood of having DVT.
Another case of DVT (specifically VTE) with deep tissue massage was reported where a 67-year-old California man with no known risk factors had a “vigorous deep tissue massage.” In 2010, the man went to the emergency care and had pain in his upper right chest, but he was discharged because radiographs and health history intake show no obvious signs of cardiovascular disease. His case was ruled to be musculoskeletal in nature and was asked to return in five days if the symptoms did not improve.
Well, it did not improve. The pain worsened, especially during any physical exertion. He went to see his primary care physician five days after the ER visit. The doctor asked him more questions about what the man did before he went to the ER, and it turned out that he had a “vigorous deep tissue massage” on his right calf for non-medical reasons. The swelling and pain in the calf began the day after the massage. Five days after the calf symptoms subsided, the chest pain began. He was given anticoagulant therapy with four days of hospitalization and was discharged in stable condition.
Therefore, every massage therapy intake must include questions that relate to cardiovascular and pulmonary health as well as lifestyle (e.g. smoking, physical activity) and mental health.
Aside from medications and compression stockings, exercise is likely your best (and cheapest) way to minimize your risk of getting DVT. However, the evidence behind exercise for such prevention is limited and uncertain.
While there is not much difference in the quality of life, risk reduction of getting post-thrombotic syndrome, and leg pain between taking morning walks and bed rest for acute DVT within 10 days, a 2019 report in DARE (Database of Abstracts of Reviews of Effects) finds that morning walks are generally safe and “may prevent or improve post-thrombotic syndrome.”
The authors of this review cited that short-term exercise, such as 30 minutes of walking on a treadmill, did not worsen DVT symptoms. Based on several trials in their review, there was no difference between the exercise and no exercise groups in recurrence of a blood clot. Because most of these results are based on one or a few randomized controlled trials or observational studies with mixed methodologies, the jury is still out on what exercise can do for DVT. But based on prior knowledge about the benefits of regular exercise, it has many health benefits that should be included in the reasons why you should continue or start to exercise regularly.
But in some cases, regular physical activity may not be enough, as in the case of my high school writing teacher, Mr. Bradshaw, who was pretty active, particularly his love of skiing and cycling. His lifestyle may have staved off DVT, but his skiing injury may have broken that defense, which went undetected during his treatment and recovery.
Deep vein thrombosis can happen to almost anyone. What is more important to consider are s the risk factors that make us more or less likely to develop this fatal condition.